Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01094886 | Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement | PHASE3 | COMPLETED | 56 | — | — | Mar 1, 2010 | Dec 1, 2010 | Mar 17, 2017 | 5 | United States |
Descriptive statistics for per-patient maximum Anti-Factor Xa laboratory value selected from the 7 consecutive blood draws (0, 2, 4, 6, 8, 12 and 24 hrs post dose) on Day 1 and Day 3
Descriptive statistics for per-patient maximum prothrombin time laboratory value selected from the 7 consecutive blood draws (0, 2, 4, 6, 8, 12 and 24 hrs post dose) on Day 1 and Day 3
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | Rivaroxaban 10mg tablet daily receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement |
| Name | Type | Description |
|---|---|---|
| Rivaroxaban | DRUG | 10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement |
Inclusion Criteria: * Undergone elective total hip or knee replacement surgery * Received postoperative venous blood clot prevention therapy within 24 hours of the surgery * Currently prescribed enoxaparin 30mg subcutaneous (SQ) twice a day or 40mg SQ daily for venous blood clotting prevention with...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 5 | PHASE4 | Undisclosed |
| Smith & Nephew plc Sponsored ADR | SNN | 3 | PHASE4 | Undisclosed |
| Johnson & Johnson | JNJ | 1 | PHASE4 | Undisclosed |